<- Go Home
ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.
Market Cap
$1.4B
Volume
1.1M
Cash and Equivalents
$39.9M
EBITDA
-$26.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$77.8M
Profit Margin
80.06%
52 Week High
$18.51
52 Week Low
$7.55
Dividend
N/A
Price / Book Value
6.09
Price / Earnings
-88.44
Price / Tangible Book Value
6.30
Enterprise Value
$1.2B
Enterprise Value / EBITDA
-44.89
Operating Income
-$27.1M
Return on Equity
6.91%
Return on Assets
-6.10
Cash and Short Term Investments
$275.7M
Debt
$69.5M
Equity
$229.0M
Revenue
$97.1M
Unlevered FCF
-$9.6M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium